Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Raily Aesthetic Medicine International Holdings Limited ( (HK:2135) ) has issued an update.
Raily Aesthetic Medicine International Holdings Limited announced the disposal of its subsidiary, Jiumei Xinhe, due to declining demand for e-PTFE facial implants and changing consumer preferences towards non-surgical procedures. The disposal aligns with the company’s strategic plan to focus on subcutaneous injection products and long-term growth, despite selling the subsidiary at a significant discount. The decision was influenced by the economic slowdown and the expiration of the subsidiary’s registration in the PRC, making the renewal costly and less viable.
More about Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited operates in the aesthetic medicine industry, focusing on aesthetic surgery services and the sale of related products, including e-PTFE facial implants and subcutaneous injection products. The company has been adjusting its market strategy due to changing consumer preferences and declining demand for surgical products.
YTD Price Performance: -14.55%
Average Trading Volume: 129,452
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$52.37M
See more data about 2135 stock on TipRanks’ Stock Analysis page.